Serotonin and mental disorders: A concise review on molecular neuroimaging evidence

Clinical Psychopharmacology and Neuroscience

Volumn 12, Issue 3, 2014, Pages 196-202

  Lin, Shih Hsien ^a,b   Lee, Lan Ting ^a   Yang, Yen Kuang ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Mental disorders; Positron emission tomography; Serotonin; Single photon emission computed tomography

Indexed keywords

SEROTONIN;

ADDICTION; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; MOLECULAR IMAGING; MOOD DISORDER; NEUROIMAGING; SCHIZOPHRENIA;

EID: 84919959094     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2014.12.3.196     Document Type: Article

References (63)

1. Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983;1:214-216.
2. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 2009;60:355-366.
3. Paterson LM, Kornum BR, Nutt DJ, Pike VW, Knudsen GM. 5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev 2013;33:54-111.
4. Zipursky RB, Meyer JH, Verhoeff NP. PET and SPECT imaging in psychiatric disorders. Can J Psychiatry 2007;52:146-157.
5. Nikolaus S, Hautzel H, Heinzel A, Müller HW. Key players in major and bipolar depression - a retrospective analysis of in vivo imaging studies. Behav Brain Res 2012;232:358-390.
6. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 1999;46:1375-1387.
7. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY- 100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000;57:174-180.
8. Hirvonen J, Karlsson H, Kajander J, Lepola A, Markkula J, Rasi-Hakala H, et al. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol 2008;11:465-476.
9. Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 2004;9:386-392.
10. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 2006;59:106-113.
11. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998;44:1090-1098.
12. Newberg AB, Amsterdam JD, Wintering N, Ploessl K, Swanson RL, Shults J, et al. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med 2005;46:973-977.
13. Joensuu M, Tolmunen T, Saarinen PI, Tiihonen J, Kuikka J, Ahola P, et al. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [(123)I] nor-beta-CIT SPECT imaging. Psychiatry Res 2007;154:125-131.
14. Ahonen A, Heikman P, Kauppinen T, Koskela A, Bergstrom K. Serotonin transporter availability in drug free depression patients using a novel SERT ligand. Eur J Nucl Med Mol Imaging 2004;31:S227-S228.
15. Catafau AM, Perez V, Plaza P, Pascual JC, Bullich S, Suarez M, et al. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. Psychopharmacology (Berl) 2006; 189:145-153.
16. Herold N, Uebelhack K, Franke L, Amthauer H, Luedemann L, Bruhn H, et al. Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM. J Neural Transm 2006;113:659-670.
17. Hsieh PC, Lee IH, Yeh TL, Chen KC, Huang HC, Chen PS, et al. Distribution volume ratio of serotonin and dopamine transporters in euthymic patients with a history of major depression - a dual-isotope SPECT study. Psychiatry Res 2010;184:157-161.
18. Hsieh PC, Chen KC, Yeh TL, Lee IH, Chen PS, Yao WJ, et al. Lower availability of midbrain serotonin transporter between healthy subjects with and without a family history of major depressive disorder - a preliminary two-ligand SPECT study. Eur Psychiatry 2014. pii: S0924-9338(13) 00445-8. [Epub ahead of print]
19. Parsey RV, Hastings RS, Oquendo MA, Huang YY, Simpson N, Arcement J, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 2006;163:52-58.
20. Reivich M, Amsterdam JD, Brunswick DJ, Shiue CY. PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter availability in major depression. J Affect Disord 2004;82:321-327.
21. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 2004;61:1271-1279.
22. Cannon DM, Ichise M, Rollis D, Klaver JM, Gandhi SK, Charney DS, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007;62:870-877.
23. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007;32:86-102.
24. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 2001; 158:1843-1849.
25. Cannon DM, Ichise M, Fromm SJ, Nugent AC, Rollis D, Gandhi SK, et al. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry 2006;60:207-217.
26. Sullivan GM, Ogden RT, Oquendo MA, Kumar JS, Simpson N, Huang YY, et al. Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. Biol Psychiatry 2009;66:223-230.
27. Chou YH, Wang SJ, Lin CL, Mao WC, Lee SM, Liao MH. Decreased brain serotonin transporter binding in the euthymic state of bipolar I but not bipolar II disorder: a SPECT study. Bipolar Disord 2010;12:312-318.
28. Freitas-Ferrari MC, Hallak JE, Trzesniak C, Filho AS, Machado-de-Sousa JP, Chagas MH, et al. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:565-580.
29. Maron E, Kuikka JT, Ulst K, Tiihonen J, Vasar V, Shlik J. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. Eur Arch Psychiatry Clin Neurosci 2004;254:392-396.
30. Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, et al. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 2007; 61:1081-1089.
31. van der Wee NJ, van Veen JF, Stevens H, van Vliet IM, van Rijk PP, Westenberg HG. Increased serotonin and dopamine transporter binding in psychotropic medication-naive patients with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT. J Nucl Med 2008;49:757-763.
32. Hesse S, Müller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, et al. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res 2005;140:63-72.
33. Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, et al. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage 2008;42:306-314.
34. Kent JM, Coplan JD, Lombardo I, Hwang DR, Huang Y, Mawlawi O, et al. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652. Psychopharmacology (Berl) 2002;164:341-348.
35. Iqbal N, van Praag HM. The role of serotonin in schizophrenia. Eur Neuropsychopharmacol 1995;5 Suppl:11-23.
36. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153: 466-476.
37. Trichard C, Paillère-Martinot ML, Attar-Levy D, Blin J, Feline A, Martinot JL. No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res 1998;31:13-17.
38. Lewis R, Kapur S, Jones C, DaSilva J, Brown GM, Wilson AA, et al. Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. Am J Psychiatry 1999; 156:72-78.
39. Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, et al. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology (Berl) 2006;189:155-164.
40. Frankle WG, Narendran R, Huang Y, Hwang DR, Lombardo I, Cangiano C, et al. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB. Biol Psychiatry 2005;57:1510-1516.
41. Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D'Souza DC, Krystal J, et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 2000;47:371-379.
42. Schmidt LG, Dufeu P, Heinz A, Kuhn S, Rommelspacher H. Serotonergic dysfunction in addiction: effects of alcohol, cigarette smoking and heroin on platelet 5-HT content. Psychiatry Res 1997;72:177-185.
43. Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex 2000;10:318-325.
44. Heinz A, Ragan P, Jones DW, Hommer D, Williams W, Knable MB, et al. Reduced central serotonin transporters in alcoholism. Am J Psychiatry 1998;155:1544-1549.
45. Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl JP, et al. Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 2001;41:275-284.
46. Cosgrove KP, Krantzler E, Frohlich EB, Stiklus S, Pittman B, Tamagnan GD, et al. Dopamine and serotonin transporter availability during acute alcohol withdrawal: effects of comorbid tobacco smoking. Neuropsychopharmacology 2009;34:2218-2226.
47. 123I]β -CIT SPECT imaging study. Psychiatry Res 2010;184: 192-195.
48. Yeh TL, Chen KC, Lin SH, Lee IH, Chen PS, Yao WJ, et al. Availability of dopamine and serotonin transporters in opioid-dependent users - a two-isotope SPECT study. Psychopharmacology (Berl) 2012;220:55-64.
49. Lin SH, Chen KC, Lee SY, Yao WJ, Chiu NT, Lee IH, et al. The association between availability of serotonin transporters and time to relapse in heroin users: a two-isotope SPECT small sample pilot study. Eur Neuropsychopharmacol 2012;22:647-650.
50. Banks ML, Czoty PW, Gage HD, Bounds MC, Garg PK, Garg S, et al. Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys. Neuropsychopharmacology 2008;33:219-225.
51. Jacobsen LK, Staley JK, Malison RT, Zoghbi SS, Seibyl JP, Kosten TR, et al. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry 2000;157:1134-1140.
52. Oades RD. Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD). Prog Brain Res 2008;172:543-565.
53. Hesse S, Ballaschke O, Barthel H, Sabri O. Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. Psychiatry Res 2009;171:120-128.
54. Karlsson L, Tuominen L, Huotarinen A, Leppämäki S, Sihvola E, Helin S, et al. Serotonin transporter in attention-deficit hyperactivity disorder - preliminary results from a positron emission tomography study. Psychiatry Res 2013;212:164-165.
55. Murphy DG, Daly E, Schmitz N, Toal F, Murphy K, Curran S, et al. Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study. Am J Psychiatry 2006;163:934-936.
56. Makkonen I, Riikonen R, Kokki H, Airaksinen MM, Kuikka JT. Serotonin and dopamine transporter binding in children with autism determined by SPECT. Dev Med Child Neurol 2008;50:593-597.
57. Nakamura K, Sekine Y, Ouchi Y, Tsujii M, Yoshikawa E, Futatsubashi M, et al. Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry 2010;67:59-68.
58. Takano A, Arakawa R, Hayashi M, Takahashi H, Ito H, Suhara T. Relationship between neuroticism personality trait and serotonin transporter binding. Biol Psychiatry 2007; 62:588-592.
59. Frokjaer VG, Vinberg M, Erritzoe D, Baaré W, Holst KK, Mortensen EL, et al. Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding. Neuropsychopharmacology 2010;35:1129-1137.
60. Koch W, Schaaff N, Pöpperl G, Mulert C, Juckel G, Reicherzer M, et al. [I-123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. J Psychiatry Neurosci 2007;32:234-240.
61. Huang HY, Lee IH, Chen KC, Lin SH, Yeh TL, Chen PS, et al. Serotonin transporter availability in the midbrain and perceived social support in healthy volunteers. J Psychosom Res 2013;75:577-581.
62. Yeh TL, Lee IH, Chen KC, Chen PS, Yao WJ, Yang YK, et al. The relationships between daily life events and the availabilities of serotonin transporters and dopamine transporters in healthy volunteers - a dual-isotope SPECT study. Neuroimage 2009;45:275-279.
63. Tsai HY, Lee IH, Yeh TL, Yao WJ, Chen KC, Chen PS, et al. Association between the dexamethasone suppression test and serotonin transporter availability in healthy volunteer: a SPECT with [(123)I] ADAM study. Eur Neuropsychopharmacol 2012;22:641-646.